07:14 AM EDT, 05/17/2024 (MT Newswires) -- Erasca ( ERAS ) said Thursday it has entered into exclusive license agreements for two preclinical RAS programs.

Erasca ( ERAS ) said the in-licensed programs subject to the agreement - pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, show the potential to address needs in almost 2.7 million patients diagnosed annually with RAS-mutant tumors, including over 2.2 million with KRAS-mutant tumors.

Erasca ( ERAS ) agreed to pay a one-time upfront cash payment of $12.5 million, up to $176.5 million in cash upon the achievement of certain milestones as well as "a low- to mid-single digit percentage" royalty to Joyo Pharmatech for the exclusive license to develop and commercialize ERAS-0015 worldwide.

Erasca ( ERAS ) will pay Medshine Discovery a one-time upfront cash payment of $10 million, up to $160 million in cash upon the achievement of certain milestones, and a low-single digit percentage royalty for the exclusive worldwide license to develop and commercialize ERAS-4001.

Price: 1.8300, Change: -0.02, Percent Change: -1.08